{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:47:04Z","timestamp":1787734024837,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jsat.2020.108141","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T22:28:01Z","timestamp":1600727281000},"page":"108141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016"],"prefix":"10.1016","volume":"119","author":[{"given":"Kirk E.","family":"Evoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Roccograndi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Covvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Ochs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa M.","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Soprano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly R.","family":"Reveles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2020.108141_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004147.pub4","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","author":"Amato","year":"2011","journal-title":"Cochrane Database System Review."},{"key":"10.1016\/j.jsat.2020.108141_bb0010","author":"Centers for Disease Control and Prevention National Center for Health Statistics"},{"key":"10.1016\/j.jsat.2020.108141_bb0015","series-title":"National practice guideline for the use of medications in the treatment of addiction involving opioid use","author":"Comer","year":"2015"},{"issue":"2","key":"10.1016\/j.jsat.2020.108141_bb0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ADM.0000000000000635","article-title":"Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder","volume":"14","author":"Crotty","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.108141_bb0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","article-title":"A meta-analytic review of psychosocial interventions for substance use disorders","volume":"165","author":"Dutra","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2020.108141_bb0030","doi-asserted-by":"crossref","first-page":"74.e11","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine","volume":"126","author":"Fiellin","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"22","key":"10.1016\/j.jsat.2020.108141_bb0035","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/archinternmed.2012.4504","article-title":"Management of substance use disorders in ambulatory care in the United States, 2001\u20132009","volume":"172","author":"Frank","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"9","key":"10.1016\/j.jsat.2020.108141_bb0040","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","article-title":"Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001\u20132002 to 2012\u20132013: Results from the national epidemiologic survey on alcohol and related conditions","volume":"74","author":"Grant","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"18","key":"10.1016\/j.jsat.2020.108141_bb0045","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jsat.2020.108141_bb0050","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/add.12266","article-title":"Comparison of behavioral treatment conditions in buprenorphine maintenance","volume":"108","author":"Ling","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2020.108141_bb0055","author":"National Institute on Alcohol Abuse and Alcoholism"},{"key":"10.1016\/j.jsat.2020.108141_bb0060","author":"National Institute on Drug Abuse"},{"key":"10.1016\/j.jsat.2020.108141_bb0065","author":"Reus"},{"issue":"11","key":"10.1016\/j.jsat.2020.108141_bb0070","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/add.14733","article-title":"Buprenorphine prescribing for opioid use disorder in medical practices: Can office-based out-patient care address the opiate crisis in the United States?","volume":"114","author":"Rhee","year":"2019","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.jsat.2020.108141_bb0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/08897077.2016.1189477","article-title":"Medication-assisted treatment for substance use disorders within a national community health center research network","volume":"37","author":"Rieckmann","year":"2016","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2020.108141_bb0080","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2020.108141_bb0085","series-title":"Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068)","author":"Substance Abuse and Mental Health Services Administration","year":"2019"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220303986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220303986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:52:35Z","timestamp":1760039555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547220303986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":17,"alternative-id":["S0740547220303986"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108141","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108141"}}